TYVASO DPI Drug Patent Profile

When do Tyvaso Dpi patents expire, and when can generic versions of Tyvaso Dpi launch?

Tyvaso Dpi is a drug marketed by United Therap and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and nine patent family members in seventeen countries.

The generic ingredient in TYVASO DPI is treprostinil. There are nineteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the treprostinil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tyvaso Dpi

A generic version of TYVASO DPI was approved as treprostinil by SANDOZ on November 30^th, 2017.

Summary for TYVASO DPI

International Patents:	109
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYVASO DPI

US Patents and Regulatory Information for TYVASO DPI

TYVASO DPI is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-005	Oct 24, 2024		RX	Yes	Yes				Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-005	Oct 24, 2024		RX	Yes	Yes			Y
United Therap	TYVASO DPI	treprostinil	POWDER;INHALATION	214324-001	May 23, 2022		RX	Yes	Yes

International Patents for TYVASO DPI

See the table below for patents covering TYVASO DPI around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I547487
South Korea	20210027546	한정된 비표면적을 갖는 디케토피페라진 마이크로입자 (DIKETOPIPERAZINE MICROPARTICLES WITH DEFINED SPECIFIC SURFACE AREAS)
European Patent Office	2314298	Microparticules comprenant des sels de diketopiperazine permettant l'administration de médicaments (Microparticles comprising diketopiperazine salts for drug delivery)

Investment Scenario and Fundamentals Analysis for TYVASO DPI

Last updated: February 20, 2026

What is TYVASO DPI?

Treprostinil inhalation powder (TYVASO DPI) is a dry powder formulation of treprostinil, a prostacyclin analogue indicated for pulmonary arterial hypertension (PAH). Developed by United Therapeutics, the product offers an inhalation route intended to improve patient compliance and reduce side effects associated with infusion therapies.

Market Overview and Growth Drivers

Pulmonary Arterial Hypertension (PAH) Market Size and Trends

• The global PAH market size was valued at USD 5.2 billion in 2022 and is projected to reach USD 8.5 billion by 2030, expanding at a compound annual growth rate (CAGR) of approximately 6.4%. (Source: Grand View Research)

• The increase in PAH prevalence, especially among populations with connective tissue diseases and congenital heart defects, supports market growth.

• Several approved therapies target different pathways (endothelin, prostacyclin, nitric oxide), creating a competitive landscape.

Product Differentiation of TYVASO DPI

• Delivery Method: Inhaled dry powder, aiming to improve ease of use over nebulized solutions.

• Advantages: Faster onset, potentially better tolerability, and fewer systemic side effects compared to intravenous or subcutaneous routes.

• Competition: Includes inhaled therapies such as inhaled treprostinil (Tyvaso), and other prostacyclins like epoprostenol and selexipag.

Market Penetration and Adoption

• Tyvaso DPI's adoption has historically been limited to specialized centers; however, patent protections and regulatory exclusivity support high-margin sales.

• The inhalation route aligns with patient preferences for non-invasive options.

Regulatory and Patent Landscape

Regulatory Status

• Tyvaso DPI received FDA approval in March 2022 for adult PAH patients requiring inhaled prostacyclin therapy.

• Approval was based on phase 3 clinical trials demonstrating efficacy in improving 6-minute walk distance (6MWD) and pulmonary hemodynamics.

Patent Position

• United Therapeutics holds key patents expiring between 2030 and 2035, protecting the formulation and delivery mechanism.

• Patent litigation or generic competition risks could influence long-term revenue.

Financial and Investment Fundamentals

Revenue and Growth

• United Therapeutics reported Tyvaso franchise (including inhaled treprostinil) revenue of approximately USD 557 million in 2022, representing roughly 35% of total company revenue.

• Tyvaso DPI, as a newer formulation, is contributing to revenue growth, but the current contribution remains proportionally small.

Profitability and Cost Structure

• Gross margins for inhaled prostacyclins are high, typically above 80%, due to the premium pricing and limited manufacturing costs.

• R&D expenditure on PAH therapies has averaged USD 150-200 million annually, with recent investments focusing on device innovation.

Competitive Position and Risks

• Market Share: Dominated by United Therapeutics' Tyvaso and Tyvaso DPI, but increasing competition from new formulations and pipelines from companies such as Actelion and Bayer poses risk.

• Pricing Pressure: Managed care and payor negotiations could threaten high-margin sales.

• Patent Expiration Risk: Potential for biosimilar or generic penetration after patent expiry could erode revenues.

Investment Considerations

• Growth Potential: The inhaled treprostinil segment is poised for expansion due to new formulations that enhance delivery and patient compliance.

• Pipeline and Development: Ongoing clinical trials for combination therapies and next-generation inhalation devices could extend product lifecycle.

• Regulatory Environment: Continued approval of similar inhaled formulations or combination drugs may pose a competitive threat.

• Financial Stability: United Therapeutics maintains a strong cash position, supporting ongoing R&D and patent defenses.

Key Takeaways

• TYVASO DPI is a high-margin specialty drug within the growing PAH market, with unique delivery advantages.

• Its revenue contribution is increasing but remains a fraction of United Therapeutics' total sales.

• Patent protection through 2030–2035 supports revenue stability in the medium term.

• Competition and patent expirations pose potential risks, requiring close monitoring.

FAQs

1. What is the primary benefit of TYVASO DPI over other PAH therapies? It offers a non-invasive inhalation route with faster onset and potentially fewer systemic side effects.

2. How does the market size influence investment outlook? The expanding PAH market supports growth, especially for innovative inhaled therapies like TYVASO DPI.

3. What are the patent expiration dates for TYVASO DPI? Key patents expire between 2030 and 2035, providing a period of market exclusivity.

4. How does competition impact TYVASO DPI’s market share? Competitors developing alternative inhaled or systemic prostacyclin formulations could erode market share.

5. What financial metrics are critical for assessing the product’s investment viability? Look at revenue growth, gross margins, R&D spending, and patent protection status.

---

References

1. Grand View Research. (2022). Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis.
2. United Therapeutics. (2023). Annual Report 2022.
3. FDA. (2022). Approval of Tyvaso DPI for Pulmonary Hypertension.
4. IQVIA. (2023). Global Markets for Pulmonary Hypertension Treatments.